Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Small-caps, PSUs and pharma remain Gautam Shah's top market themes for 2026
Gautam Shah, Founder of Goldilocks Global Research, sees the Nifty remaining range-bound between 23,150 and 24,000, while forecasting the small-cap index could rise to 20,000. Shah also believes Indian IT stocks are nearing a bottom and that PSU stocks could deliver 25-30% returns over the next 12-18 months.
BofA sees domestic growth, Semaglutide opportunity driving pharma in FY27
Neha Manpuria, Senior Analyst - Pharma, Healthcare at BofA Global Research, says semaglutide launches could emerge as a key growth driver for Indian pharma companies in FY27.
Stocks to buy today: Sudeep Pharma, Rubicon Research, ICICI Prudential AMC
Stocks to buy today: Aakash Shah of Choice Broking has recommended buying three stocks today - Rubicon Research, Sudeep Pharma, and ICICI Prudential Asset Management.
Reliance operationalises clean energy giga complex; elevates national exchequer contribution to Rs 2,16,472 crore in FY26
Reliance Industries has launched its clean energy operations. The company commissioned solar module manufacturing and began advanced work on a battery storage giga-factory. Reliance also significantly increased its contributions to the national exchequer. Jio Platforms accelerated its research and development, filing numerous new patents. The company is focused on enabling India's energy and digital future.
Stocks to Watch today: Coal India, PhysicsWallah, ONGC, Siemens, IRCTC
Stocks to Watch today, May 27, 2026: MobiKwik, Sun Pharma, J&K Tyre, and Elgi Equipments are among some of the top stocks to remain in focus during today's trading session
Sun Pharma sees steady FY27 growth, progresses $11.75 bn Organon integration deal
Sun Pharma anticipates strong growth in the coming years. The company expects a high single-digit increase in its overall sales by FY2027. Significant progress is being made on the acquisition of Organon, with completion targeted for the last quarter of FY2027. This strategic move is set to enhance Sun Pharma's global presence and product portfolio across key therapeutic areas.
Q4 Results Today: Colgate Pamolive, Eicher Motors, Hindalco, Sun Pharma, NTPC Green, Ircon And More — Check Estimates
The list of companies scheduled to report Q4 results on May 22 also includes 20 Microns, 3M India, Century Plyboards (India), DAM Capital Advisors, Electronics Mart India and more.
Sun Pharma Q4 Preview: Can Unloxcyt and speciality drugs help pharma major deliver another strong quarter?
Sun Pharma is expected to post double-digit revenue growth in Q4FY26, driven by strong performance across speciality drugs, domestic formulations, and emerging markets. Brokerages highlight US portfolio strength, new launches like Unloxcyt, and a steady margin outlook despite higher R&D spending, with EBITDA growth supported by diversified global business momentum outlook
Q4 Results LIVE Updates: Sanghvi Movers shares surge over 12%; Jubilant Foodworks down 7%
Q4 Results LIVE Updates: ITC, Aurobindo Pharma, LIC, LG Electronics, Ashoka Buildcon, Bikaji Foods, Datamatics, Engineers India, GMM Pfaudler, Happy Forgings, Honasa Consumer, Ixigo, Nykaa, Page Industries, Ramco Cements, Max Healthcare, Prestige Estates, MTNL, Sun TV, Quick Heal, RCF, WeWork, VA Tech Wabag, are among the companies reporting their earnings today. The street will also react to numbers reported by Whirlpool, Apollo Hospitals, Sammaan Capital, JK Lakshmi Cement, Lenskart, Ola Electric and others. Watch this space for all the LIVE earnings updates.
Vinay Rajani of HDFC Sec suggests Oracle Financial Services, Sun Pharma shares to buy
Indian equity markets experienced a significant selloff on May 18, with Sensex and Nifty 50 dropping over 1%. The BSE Sensex fell over 1,000 points, erasing nearly ₹9 lakh crore in investor wealth amid weak global cues and a bearish trend across sectors.
Sun Pharma explores funding mix for $12 billion Organon deal
Global lenders are exploring various financing options for Sun Pharmaceutical Industries' proposed $12 billion acquisition of Organon & Co. The Indian drugmaker is considering swapping Organon bondholders into Sun Pharma debt and a potential euro-denominated bond. Additionally, Sun Pharma plans to raise $3 billion to $4 billion in offshore loans, with deal approvals anticipated by December.
Where to invest now: SBI MF prefers large caps, pharma, PSU banks
Ruchit Mehta, Head of Research at SBI Mutual Fund, prefers CDMO and hospital plays within pharma, citing stronger growth prospects over generics. He sees large caps as attractive on valuations, while midcaps require selectivity amid earnings risks. PSU banks may outperform in the near term due to stronger loan growth, but asset quality risks could emerge over the next 2–3 quarters if global disruptions persist.